Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Sperling

Vascular & Interventional Radiology New York, NY Medical Doctor

NPI 1255339420 CMS profile 102284

1275 York Ave, New York, NY 10065

Open in the dashboard

General payments

$42,479

87 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Sperling of New York, NY is reported in the CMS Open Payments database as having received $42,479 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,770 6
2024 General $11,134 19
2023 General $3,167 10
2022 General $2,832 11
2021 General $1,009 6
2020 General $3,525 8
2019 General $16,043 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Sperling
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to David Sperling were reported at $4,770. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year David Sperling Vascular & Interventional Radiology median Middle half National median
2019 $16,043 $422 $125–$1,555 $163
2020 $3,525 $200 $68–$652 $114
2021 $1,009 $280 $99–$866 $132
2022 $2,832 $433 $137–$1,497 $149
2023 $3,167 $506 $152–$2,019 $160
2024 $11,134 $556 $175–$1,930 $164
2025 $4,770 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $20,533 31 payments
  2. Siemens Medical Solutions USA, Inc. $13,769 23 payments
  3. Merit Medical Systems Inc $6,351 3 payments
  4. Ortho Dermatologics, a division of Bausch Health US, LLC $440 1 payment
  5. Surefire Medical, Inc. $354 2 payments
  6. Penumbra, Inc. $344 8 payments
  7. Philips Electronics North America Corporation $172 2 payments
  8. Bard Peripheral Vascular, Inc. $139 1 payment
  9. Boston Scientific Corporation $92 4 payments
  10. Terumo Medical Corporation $70 3 payments
  11. Other $216 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,850 16 payments
  2. Honoraria $12,000 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,250 5 payments
  4. Travel and Lodging $3,422 8 payments
  5. Food and Beverage $2,517 53 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $440 1 payment
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $20,533 31 payments
  2. SALEX $440 1 payment
  3. TRINAV INFUSION SYSTEM $354 2 payments
  4. Indigo System $281 2 payments
  5. EPIQ 7G $172 2 payments
  6. Denali Vena Cava Filter $139 1 payment
  7. Varian CRYOCARE TOUCH System $117 1 payment
  8. Cios Spin $88 4 payments
  9. Azur CX Detachable $70 3 payments
  10. Embozene $63 1 payment
  11. Other $381 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$368,213

Of which drugs: $380

Medicare patients

189

Average age 74

Services billed

3,689

87 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 40%
Ischemic heart disease 37%
Chronic kidney disease 36%
Cancer 31%
COPD 26%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 11 1,538 $164
Injection, fentanyl citrate, 0.1 mg J3010 Office 21 23 $17
Injection, acetaminophen, not otherwise specified,10 mg J0131 Office 11 426 $16
Injection, midazolam hydrochloride, per 1 mg J2250 Office 26 45 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record